

SETBP1 Haploinsufficiency and Related Disorders Clinical and Neurobehavioral Phenotype Study

Authors

- Haley O. Oyler, SETBP1 Society, Austin, TX 78703
- Caitlin M. Hudac, Department of Psychology and Carolina Autism and Neurodevelopmental Research Center, University of South Carolina, Columbia, SC, 29201
- Wendy K. Chung, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115
- LeeAnne G. Snyder, Simons Foundation, New York, NY, 10010
- Stephanie Robertson, Associate Professor of Psychological Sciences and Director of the Tarleton Center for Child Well-being, Tarleton State University, Stephenville, TX 76402
- Siddharth Srivastava, Department of Neurology, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115
- Trina Geye, Associate Professor of Psychological Sciences, Tarleton State University, Stephenville, TX 76402

Corresponding Author: Haley Oyler, haley@setbp1.org, 512-522-8072

Abstract

To comprehensively investigate the neurodevelopmental profile and clinical characteristics associated with SETBP1 haploinsufficiency disorder (SETBP1-HD) and SETBP1-related disorders (SETBP1-RD). We reported genetic results on 34 individuals, with behavior and clinical data from 22 with SETBP1-HD and 5 with SETBP1-RD, by assessing results from medical history interviews and standardized adaptive, clinical, and social measures provided from Simons Searchlight. All individuals with SETBP1-HD and SETBP1-RD exhibited neurological impairments including intellectual disability/developmental delay (IDD), attention-deficit/hyperactivity disorder, autism spectrum disorder, and/or seizures, as well as speech and language delays. While restricted interests and repetitive behaviors present challenges, a relative strength was observed in social motivation within both cohorts. Individuals with SETBP1-RD reported a risk for heart issues and compared to SETBP1-HD greater risks for orthopedic and somatic issues with greater difficulty in bowel control. Higher rates for neonatal feeding difficulties and febrile seizures were reported for individuals with SETBP1-HD. Additional prominent characteristics included sleep, vision, and gastrointestinal issues, hypotonia, and high pain tolerance. This characterization of phenotypic overlap (IDD, speech challenges, autistic and attention deficit traits) and differentiation (somatic and heart issue risks for SETBP1-RD) between the distinct neurodevelopmental disorders SETBP1-HD and SETBP1-RD is critical for medical management and diagnosis.

INTRODUCTION

SETBP1

SETBP1 (HGNC:15573), *SET binding protein 1* is a dosage-sensitive gene located at 18q12.3 that encodes a regulatory protein essential to human brain development.^{1,2} *SETBP1* functions as a transcription factor involved in cell cycle control, gene expression through modulation of chromatin accessibility, and regulation of transcription and is implicated in speech and language development.^{2,3,4}

SETBP1-related Neurodevelopmental Disorders

Variants in *SETBP1* are associated with three different phenotypes: 1. Schinzel-Giedion Syndrome (SGS), 2. *SETBP1* haploinsufficiency disorder (*SETBP1*-HD), and 3. *SETBP1*-related disorders (*SETBP1*-RD).

SGS (OMIM #269150) is a rare, often progressive, neurodevelopmental disorder characterized by distinct facial features, skeletal, neurological, cardiovascular, and congenital anomalies with increased risk of malignancy.^{5,6,7} *SETBP1* variants associated with SGS are isolated to a specific amino acid region on *SETBP1* (868-871).⁸ Prior literature identified a sub-category called atypical SGS for individuals with variants located adjacent to or close by the classical SGS amino acid region (862-867,872-873) with less severe symptoms and a potentially longer life expectancy, past the first decade in life.⁶ Diagnosis is often made initially based on physical, clinical presentation and verified with genetic testing.

SETBP1-HD (OMIM #616078) is a rare neurodevelopmental disorder characterized by speech/language impairment, intellectual disability/developmental delay (IDD/DD), hypotonia, attention deficits, vision impairment, characteristic facial features, and autistic traits.^{1,4,9} *SETBP1* variants associated with *SETBP1*-HD span the length of the *SETBP1* gene. Although a prior publication noted some subtle and less recognizable facial differences in 93% of individuals with *SETBP1*-HD which are distinct from SGS, including ptosis, broad nasal bridge, hypertelorism, full nasal tip, high palate and blepharophimosis, the differences are not sufficiently distinct for a clinical presentation diagnosis and therefore diagnosis of *SETBP1*-HD is determined by genetic testing.⁹

In general, loss of function *SETBP1* variants are associated with *SETBP1*-HD, whereas gain of function *SETBP1* variants are associated with SGS. A third, novel category comprises variants associated with *SETBP1*-RD due to pathogenic missense variants located outside the classical and atypical SGS region (862-873) or in-frame deletions, with DNA-binding and transcription function independent of *SETBP1* protein abundance.^{6,10,11} All *SETBP1*-related neurodevelopmental disorders are autosomal dominant and primarily de novo, with rare cases resulting from inherited mutations.^{10,12}

Summary

Knowledge is limited for the neurodevelopmental impact and phenotypic consequences of *SETBP1* changes, particularly for variants that lead to SETBP1-HD and SETBP1-RD.^{1,2,10,13} Here, we present the first comprehensive cross-sectional and longitudinal, when available, comparative summary of behavioral and clinical phenotypes for SETBP1-HD and SETBP1-RD. This paper includes neurodevelopmental impact and phenotypic characteristics for 22 cases; 12 previously unpublished cases of SETBP1-HD and 6 previously unpublished cases of SETBP1-RD. Limited extant literature describes the neurodevelopmental profile and clinical characteristics of individuals with SETBP1-HD and SETBP1-RD, which critically impairs understanding of the disorders, thereby hindering access to an accurate diagnosis, proper care, and medical management.^{4,7,10,11,14} To date, there are no treatments specific to SETBP1-HD or SETBP1-RD; a well-established neurodevelopmental and clinical profile of the disorders is a vital step on the path to developing standard of care guidelines and targeted treatments for affected individuals.

MATERIALS AND METHODS

Simons Searchlight Data Collection

For this publication, we analyzed Simons Searchlight (Searchlight) data from participants with SETBP1 variants. Searchlight is an international research program by the Simons Foundation Autism Research Initiative (SFARI) aiming to characterize the natural history of rare genetic neurodevelopmental disorders caused by a single gene or copy number variant. Caregivers register online with Searchlight, then complete a medical history screener and interview (MHI) with a licensed genetic counselor as well as a series of standardized caregiver-reported questionnaires online. Genetic reports are uploaded and variants are confirmed for pathogenicity. Many of the online instruments are administered annually to obtain longitudinal data for participants. SETBP1 Society is a 501(c)3 non-profit with a mission to provide support for families affected by SETBP1-HD and SETBP1-RD. The society functions to promote and fund research, bring awareness and education to the public, and to unite the community. One way the society upholds its mission is through the promotion and recruitment for Searchlight. As an extension of its mission, the organization partnered with Tarleton State University to develop the SETBP1 Community Research Study (SCoReS) study. SCoREs is a community based participatory research (CBPR) project designed to be iterative and ongoing with a focus on intervention development with equal partnership between the community and the researcher team.¹⁵ The SETBP1 Searchlight v10 and v11 data for this publication were extracted from the SFARI Base database on July 7, 2022 and January 24, 2023.

Verification and Classification

Of the 34 individuals with a SETBP1-HD or SETBP1-RD diagnosis, whole exome sequencing (WES) was the most common method for identifying SETBP1-HD and SETBP1-RD, 80% of the participants. The additional genetic tests that identified the diagnosis were Chromosomal microarray analysis (CMA) and whole genome sequencing (WGS), as well as targeted panels, including the Autism/ID Xpanded Panel, EpiXpanded Panel, Epileptome and Congenital Hypotonia Xpanded Panel.

We included participants with pathogenic or likely pathogenic SETBP1 variants or deletions who were categorized into one of two groups: SETBP1-HD, comprising individuals with SETBP1 loss-of-function (nonsense, frameshift) variants or with intragenic or full deletions of SETBP1 affecting up to 2 adjacent genes, and SETBP1-RD, comprising individuals with missense SETBP1 variants located outside the classical and atypical SGS region (862-873). Individuals with a Variant of Uncertain Significance (VUS), SGS or SETBP1 groups (deletions encompassing SETBP1 and 3 or more additional genes or splice site variants) with less than 3 individuals with data were excluded. For a complete list of SETBP1 variants included in Searchlight, see [Supplementary Table 1](#).

Standardized Measures

The Vineland Adaptive Behaviors Scales, third edition (VABS-3) assesses adaptive functioning necessary for individuals to live as independently and to function as safely and appropriately in daily life as possible, given their age.¹⁶ Adaptive behaviors include practical skills like grooming, safety, following rules, ability to work, taking care of oneself and their environment, making friends, social ability, and personal responsibility. This standardized measure has motor, communication, daily living skills, and socialization domains, resulting in an overall Adaptive Behavior Composite (ABC) score.

The caregiver-reported Child Behavior Checklist (CBCL) uses a 3-point Likert scale to assess an array of behavioral and emotional concerns in children by providing broadband, narrowband, and DSM-5 oriented scales.^{17,18,19} Both the Child Behavior Checklist 1½ -5 (CBCL/1½-5) for preschool children and the Child Behavior Checklist 6-18 (CBCL/6-18) for school-age children were administered within Searchlight based on developmental level and appropriateness.

The Social Responsiveness Scale, Second Edition (SRS-2) School Age measures social deficits and other symptoms related to autism spectrum disorder (ASD) observed in natural settings, using a 4-point Likert scale.²⁰ The SRS-2 provides a total score and five treatment subdomain scores: social awareness, social cognition, social communication, social motivation, and restricted interests and repetitive behaviors.

The Social Communication Questionnaire – Lifetime (SCQ) is a caregiver-report screening measure that assesses the presence or absence of symptomatology associated with ASD for

children over the age of 4 years.²¹ The SCQ yields a single total score with a cutoff score of ≥ 15 , used as an indication of a possible ASD diagnosis and indicates the need for further comprehensive evaluation.

The Children's Sleep Habits Questionnaire (CSHQ) is a caregiver-report tool developed to evaluate sleep patterns and problems in children aged 2–17 years using a 3-point Likert scale.^{22,23} A total score of 41 is reported to be a sensitive clinical cutoff score for identifying probable sleep problems. Eight subscale scores are calculated with higher scores for these subscales indicating more sleep problems.

Additional Searchlight surveys reviewed included the Seizure Survey, Sleep Supplement, Brief Developmental Update and Background History Form.

When sufficient longitudinal data were reported for the standardized measures, as determined by more than half of caregivers completing the survey more than once, all data points were considered for age-relevant trends with statistical controls (i.e., random intercept per person) to account for the multiple time points. If only cross-sectional data were reported for specific surveys, then the most recent evaluation was included for each individual.

RESULTS

Genotype & Demographics

Of the 58 participants with genetic reports associated with SETBP1 in Searchlight, 28 individuals have a confirmed diagnosis of SETBP1-HD; 16 male and 12 female. Individual 17 had an additional likely pathogenic variant in the *CHD7* gene, inherited from a parent, who did not exhibit the symptoms of CHARGE syndrome, which is a separate disorder that can be caused by pathogenic *CHD7* variants. Individual 28 had a likely pathogenic variant in the *SDHB* gene but was not included in the phenotypic analysis due to missing data. No other additional pathogenic variants were determined in the remaining 26 participants in the SETBP1-HD group. Six individuals had a pathogenic or likely pathogenic missense SETBP1 variant located outside the atypical and classical SGS region and comprised the SETBP1-RD group ([Table 1](#)). In the case where the inheritance is known, all SETBP1 variants associated with SETBP1-HD and SETBP1-RD were reported as de novo.

Twelve of the 28 individuals with SETBP1-HD had a confirmed nonsense variant while 13 had a frameshift variant and 3 had a partial deletion of the SETBP1 gene. All of the deletions and variants were unique except for 3 individuals with the p.(Arg625*) variant, 2 individuals with the p.(Arg530*) variant and 2 individuals with the p.(Arg626*) variant. The 6 individuals with SETBP1-RD had missense variants and 4 of which shared the same variant, p.(Glu858Lys) ([Table 1](#)). Of note, 12 of the individuals with SETBP1-HD and all 6 of the individuals with SETBP1-RD are not included in prior literature ([Figure 1](#)).

Table 1 Genomic and Demographics

ID	Age	Sex	Inheritance Status	Type of Variant	ACMG	Protein Change	Coding Change	Other Pathogenic Variant
SETBP1-HD Participants								
p1 [†]	0-5	F	Unknown	Nonsense	LP	p.(Gln89*)	c.265C>T	
p2	0-5	M	De novo	Frameshift	P	p.(Lys152Trpfs*18)	c.453_454insTGGG	
p3 [†]	6-10	M	De novo	Nonsense	P	p.(Gln178*)	c.532C>T	
p4	6-10	M	De novo	Frameshift	P	p.(Arg243Leufs*98)	c.726_732del	
p5 [†]	11-15	M	De novo	Nonsense	P	p.(Trp274*)	c.821G>A	
p6 [†]	6-10	M	De novo	Nonsense	P	p.(Met470*)	c.1408del	
p7	6-10	M	De novo	Frameshift	P	p.(His523Leufs*32)	c.1568del	
p8	0-5	F	De novo	Nonsense	P	p.(Arg530*)	c.1588C>T	
p9 [†]	6-10	F	De novo	Nonsense	P	p.(Arg530*)	c.1588C>T	
p10 [†]	21-25	F	De novo	Frameshift	P	p.(Ser540Thrfs*15)	c.1619del	
p11	6-10	M	De novo	Frameshift	P	p.(Pro559Argfs*21)	c.1676del	
p12 [†]	6-10	M	Unknown	Frameshift	LP	p.(Gly588Aspfs*42)	c.1763del	
p13	11-15	M	De novo	Nonsense	LP	p.(Arg589*)	c.1765C>T	
p14	11-15	M	Unknown	Frameshift	P	p.(Ser608Alafs*22)	c.1821del	
p15	0-5	F	De novo	Nonsense	P	p.(Arg625*)	c.1873C>T	
p16	12.5	M	De novo	Nonsense	P	p.(Arg625*)	c.1873C>T	
p17 [†]	6-10	M	De novo	Nonsense	P	p.(Arg625*)	c.1873C>T	CHD7 c.5051-2A>C LP, PI
p18	6-10	F	De novo	Nonsense	P	p.(Arg626*)	c.1876C>T	
p19 [†]	21-25	M	Unknown	Nonsense	P	p.(Arg626*)	c.1876C>T	
p20 [†]	11-15	M	De novo	Frameshift	P	p.(Asp757Cysfs*23)	c.2269_2281del arr[GCRh37] 18q12.3 (40846809-42883959)x1	
p21 [†]	0-5	F	Unknown	Deletion	P	SETBP1 Deletion	arr[GRCh37] 18q12.3 (40034922-42755922)x1	
p22 [†]	0-5	M	Unknown	Deletion	P	SETBP1 Deletion	arr[GRCh37] 18q12.3 (40034922-42755922)x1	
p23	6-10	M	De novo	Frameshift	P	p.(Ala113Leufs*94)	c.337del	
p24	11-15	F	De novo	Frameshift	P	p.(Ser142Valfs*7)	c.422 dup	
p25 [†]	0-5	F	De novo	Frameshift	P	p.(Pro208Glnfs*135)	c.623del	
p26 [†]	15-20	F	De novo	Frameshift	P	p.(Gly268Alafs*75)	c.801del	
p27 [†]	6-10	F	De novo	Frameshift	LP	p.(*1597Trpext*7)	c.4790_*9del arr[GCRh37] 18q12.3 (42281312-42643731)x1	SDHB c.589C>T LP, IU
p28 [†]	0-5	F	Unknown	Deletion	P	Deletion of exon 2-6		
SETBP1-RD Participants								
p29 [†]	6-10	F	De novo	Missense	LP	p.(Ser854Phe)	c.2561C>T	
p30 [†]	6-10	F	De novo	Missense	LP	p.(Glu858Lys)	c.2572G>A	
p31 [†]	0-5	F	De novo	Missense	LP	p.(Glu858Lys)	c.2572G>A	ATM c.7271T>G LP, MI
p32 [†]	0-5	F	De novo	Missense	LP	p.(Glu858Lys)	c.2572G>A	
p33 [†]	16-20	M	De novo	Missense	P	p.(Asp874Gly)	c.2621A>G	NBAS c.2950del LP, MI
p34 [†]	6-10	M	De novo	Missense	LP	p.(Glu858Lys)	c.2572G>A	

Table 1: [†]Not published in prior publications; Age, latest assessment age in range of years; LP, likely pathogenic; P, pathogenic; Y, yes; N, no; MI, maternally inherited; PI, paternally inherited; IU, inheritance unknown; ACMG, American College of Medical Genetics Classification. The HGVS nomenclature for variants was validated using Variant Validator.²⁵




Figure 1: Schematic representation of SETBP1 protein (UniProt: Q9Y6X0), including its domains, indicating SETBP1-HD variants above and SETBP1-RD variants below with blue dots representing novel individuals and orange dots indicating individuals in prior publications. Two individuals with larger deletions (p21, p22) are not shown here. For cDNA annotations of the variants see Table 1.

Six of the 28 SETBP1-HD participants and 1 of the 6 SETBP1-RD participants had no medical history, background, or behavioral results and were not included further in this publication.

Clinical Results/Clinical Findings

SETBP1-HD

Summary clinical characteristics for 22 (15 male and 7 female, age range = 2.2-24.25 years) SETBP1-HD participants are provided ([Table 2](#)). Of note, not all individuals completed the MHI or the background history form resulting in missing data ([Supplementary Table 2](#)). Speech and language difficulties were reported by 100% of participating individuals based on speech delays, speech disorders, language disorders, or delayed first words (>12 months).²⁵ Neurological manifestations were reported including 95% ID/DD, 74% hypotonia, and 26% clumsiness/incoordination. Attention-Deficit/Hyperactivity Disorder (ADHD) and/or medications for attention issues were reported in 65%.²⁶ An ASD diagnosis was reported by 21% >= 2 years, with 75% having comorbid ASD and ADHD diagnoses; 0% reported autistic regression.²⁷ Autistic traits were noted in 56%; based on elevated scores for one or more of the following: T >= 60 SRS-2 total, T >= 70 on CBCL/6-18 social, attention and thought problems scales, or T

≥ 65 for the CBCL/1½–5 DSM ASD domain.^{20,28} Sleep issues were reported in 50% and neonatal feeding difficulties in 42%.

In terms of medical issues, 21% of participants reported febrile seizures, of which 1 individual reported an epilepsy diagnosis. A high pain tolerance was reported in 57%, gastrointestinal issues in 53%, failure to thrive in 16%, and anxiety also in 16%. Vision issues were reported in 58%, with farsightedness as the most prevalent issue. Surgeries were noted in 58% with a majority being minor surgeries, including tongue-tie in 21%, PE tubes for 21%, and an adenoidectomy in 14%. Dermatological issues were reported for 37% with eczema being the most commonly reported. Various orthopedic issues were reported by 16%, as well as 16% reporting undescended testicles as the only noted genital issue. Toilet training occurred for 77% with success ranging from 2-9 years of age and bowel control occurred for 68% with success ranging from 2.8-9 years of age.

SETBP1-RD

Summary clinical characteristics for 5 (4 female and 1 male, age range = 3-14.9 years) SETBP1-RD participants are provided ([Table 2](#)). IDD/DD and speech and language issues as well as hypotonia and sleep issues were identified in 100% of participants. Distinct orthopedic issues were reported in 3 individuals, as well as gastrointestinal issues, with constipation being the most common symptom. Heart issues were reported in 2 individuals. Two individuals reported astigmatism as the only vision issue. Seizures in the form of infantile spasms were reported in 1 individual, with 1 other individual reporting suspected absence seizures. Distinct surgeries were noted in 3 individuals and movement disorders were noted in 2 individuals ([Supplementary Table 2](#)). A genital issue of hypospadias was noted in 1 individual. Toilet training occurred for 2 individuals with success ranging from 5 to 7+ years of age and bowel control occurred for 1 individual with success reported at 7+ years of age.

No individuals with SETBP1-HD or SETBP1-RD reported a diagnosis of cancer, which is worth mentioning as somatic SETBP1 variants have been linked to certain blood cancers.³ Additionally, individuals with SGS have a higher risk for tumors and malignancy further delineating from the individuals with SETBP1-HD and SETBP1-RD.^{6,28}

Table 2 Clinical Characteristics

	SETBP1-HD		SETBP1-RD	
	%	min-max age, total	%	min-max age, total
Last Age at Evaluation		2.3-24.3yr, n=22		3-14.9yr, n=5
	%	min-max age, n=symptom/total	%	min-max age, n=symptom/total
Pregnancy and neonatal				
complications during pregnancy	56%	n=10/18	75%	n=3/4
gestational age	38wk	35-42wk, n=17	38wk	36-39wk, n=4
feeding difficulty	42%	n=8/19	0%	n=0/4
	%	min-max age, n=symptom/total	%	min-max age, n=symptom/total
Neurodevelopmental and psychiatric				
delayed walking [skill gained]	68%	1-3.5yr, n=13/19 [94.7%]	100%	1.5-4yr, n=5/5 [100%]
delayed first words [†] [skill gained]	100%	1.1-4yr, n=17/17 [88.9%]	100%	1.1-5.5yr, n=5/5 [100%]
delayed combined words [skill gained]	100%	2.5-8yr, n=15/15 [80%]	100%	4.5-over 7yr, n=3/3 [66.7%]
toilet trained [‡]	80%	2-9yr, n=10/13	67%	5-over 7yr, n=2/3
bowel trained [‡]	69%	2.8-9yr, n=9/13	33%	over 7yr, n=1/3
	%	n=symptom/total	%	n=symptom/total
speech delay or language disorder	100%	n=21/21	100%	n=5/5
ID or DD [§]	95%	n=19/20	100%	n=5/5
ADHD or ADHD meds [¶]	65%	n=11/17	50%	n=2/4
ASD	21%	n=4/19	25%	n=1/4
autistic traits ^{††}	56%	n=10/18	100%	n=5/5
anxiety disorder	16%	n=3/19	0%	n=0/4
sensory integration disorder	11%	n=2/19	0%	n=0/4
neuro seizure	5%	n=1/19	20%	n=1/5
febrile seizure	21%	n=4/19	0%	n=0/4
hypotonia	74%	n=14/19	100%	n=4/4
failure to thrive	11%	n=3/19	25%	n=1/4
microcephaly	47%	n=2/19	0%	n=0/4
sleep issues	26%	n=7/15	100%	n=4/4
clumsy	57%	n=5/19		
high pain threshold	16%	n=8/14	50%	n=1/2
Systemic				
Vision	58%	n=11/19	50%	n=2/4
farsighted	32%	n=6/19	0%	n=0/4
nearsighted	11%	n=2/19	0%	n=0/4
crossed eyes	11%	n=2/19	0%	n=0/4
ptosis	11%	n=2/19	0%	n=0/4
lazy eye	5%	n=1/19	0%	n=0/4
astigmatism	5%	n=1/19	50%	n=2/4
Gastro	53%	n=10/19	75%	n=3/4
constipation	26%	n=5/19	75%	n=3/4
diarrhea	32%	n=6/19	25%	n=1/4
GERD	26%	n=5/19	50%	n=2/4
dermatological	37%	n=7/19	25%	n=1/4
Orthopedic	16%	n=3/19	75%	n=3/4
Heart	0%	n=0/19	50%	n=2/4

	Genital	16%	n=3/19	25%	n=1/4
	Surgeries	58%	n=11/19	75%	n=2/4
Cancer		0%	n=0/19	0%	n=0/4

Table 2: [†]One SETBP1-HD individual spoke but exact age is unknown so individual is excluded from delayed first words total but is included in the skill gained percentage. [‡]Data from CBCL/6-18 augmented the caregiver reported toilet trained/bowel trained data; [§]DD label provided if reported diagnosis or a reported speech delay and gross motor skills delay by at least 2 SDs below the norm as identified by delayed walking after 15.7 months.³⁰ ID label given only if the caregiver reported the diagnosis; [¶]over 4 years old; ^{**}elevated scores for one or more of the following: ≥ 60 SRS-2 total T-score, ≥ 70 for CBCL/6-18 social and thought problems scales, or ≥ 65 for the CBCL/1½-5 DSM ASD domain; wk, weeks; yr, years; symptom, number of individuals with the symptom; total, total number of individuals included in the sample.

Behavioral Results

Vineland-3

Vineland-3 data were available for 13 (9 male, age range = 2.3-24 years) SETBP1-HD participants. Borderline to mild impairments were noted across all domains, as reflected by their standard score means. Mild impairment was noted at the group level in the communication (66.7) domain. Borderline impairments were noted for the group in the following domains: socialization (79.3), motor skills (72.4), daily living skills (74.5) and ABC (72.5, range = 59-84). For the subdomain v-scores, expressive (9.7), written (7.2), community (8.7) and fine motor (9.7) fell in the low range for group means ([Table 3](#)). At the individual level, scores fell in the moderately low to low range in 82% of the subdomain scores, within the borderline to mild range in 81% of the domain scores, and below the adequate level in 90% of the domain scores. Notably, 100% fell below the adequate level in communication (including receptive and written), motor (including gross motor), community within daily living skills, and overall adaptive functioning. An area of relative strength was interpersonal relationships in the socialization domain with 46% in the adequate level ([Supplementary Table 3](#)).

The SETBP1-RD group included Vineland-3 data for only 2 individuals (both female, age range = 2.7-9.2 years) with results falling in the SETBP1-HD groups' defined ranges for each domain ([Table 3](#)).

Table 3 SETBP1-HD Vineland-3

VABS-3 Domains (n=13)	Mean (SD)	Median	Range	Impairment Levels
Communication [†]	66.7 (12.3)	73	45-83	Mild
Expressive [‡]	9.7 (3.4)	10	1-15	Low
Receptive [‡]	10.2 (1.8)	10	6-12	Moderately Low
Written [¶]	7.2 (3.1)	8	1-10	Low
Daily Living Skills [†]	74.5 (16.7)	73	54-118	Borderline
Personal [‡]	10.8 (3.8)	10	7-21	Moderately Low
Domestic [¶]	11.4 (3.7)	11	7-21	Moderately Low
Community [¶]	8.7 (2.6)	9	3-12	Low
Social [†]	79.3 (13.7)	76	56-108	Borderline
Interpersonal Relationships [‡]	11.5 (2.5)	11	8-15	Moderately Low
Play & Leisure [‡]	11.7 (3)	11	8-18	Moderately Low
Coping Skills ^{‡,††}	10.7 (2.6)	11	7-16	Moderately Low
Motor [†]	72.4 (5.5)	73	65-79	Borderline
Gross Motor ^{‡,§}	10 (1.6)	9	8-12	Moderately Low
Fine Motor [‡]	9.7 (2.4)	10	7-13	Low
ABC/Composite [†]	72.5 (8.6)	71	59-84	Borderline

Table 3: A mean of 100 and SD=15 apply to composite and domain scores, while a mean of 15 and SD=3 apply to subdomain scores. [†]Domain standard score means interpretations reference: scores between 70–84 reflect borderline impairment, 55–69 reflect mild impairment, 40–54 reflect moderate impairment and 25–39 reflect severe impairment. Lower scores reflect greater impairment. [‡]Subdomain scale v-score interpretations reference: 21+ reflect high scores, 18-20 reflect moderately high scores, 13-17 reflect adequate scores, 10-12 reflect moderately low scores, and 1-9 reflect low scores. [§]Motor skills v-scores were provided for individuals <9 years old, which includes 6 of the 13 individuals. [¶]Written, domestic and community v-scores were provided for individuals ≥3 years. ^{††}Coping skills v-scores were provided for individuals ≥2 years.

Child Behavior Checklist (CBCL)

CBCL/6-18 data were available for 12 SETBP1-HD (10 male and 2 female, age range = 6.3-14.3 years) and 3 SETBP1-RD (2 female and 1 male, age range = 10-16 years) participants. CBCL/1 ½-5 data were available for 8 SETBP1-HD (5 female and 3 male, age range = 2.2-6 years) and 3 SETBP1-RD (all female, age range = 3.1-5.5 years) participants.

First, we considered the broadband scales including total problems, internalizing problems, and externalizing problems, as summarized in [Figure 2A](#). For total problems, the mean score was in the borderline range for SETBP1-HD school-age participants (range = 51-77), SETBP1-RD school-age participants (range = 54-74), and SETBP1-RD younger participants (range = 38-81) ([Figure 2A](#)).

A series of ANOVAs of broadband scales evaluated full-factorial effects between SETBP1 group, age, and CBCL measure. An overall age effect, $F(1, 18) = 5.61, p = .030$, suggested that total problems increased as children got older; however, an interaction between group, measure, and age, $F(1, 18) = 10.22, p = .005$, indicated that this effect was stronger for

SETBP1-HD relative to SETBP1-RD, $p = .049$. A similar pattern was observed for externalizing, $F(1, 18) = 11.42, p = .003$. Age effects are illustrated in [Figure 2B](#).

Narrowband scales are described separately in the following sections for each version of the CBCL using similar statistical approaches but without the effect between measurements since models were run separately for CBCL/1.5-5 and CBCL/6-18.




Figure 2: Cross-sectional effects for broadband scales on Child Behavior Checklists. The higher the value, the more severe the symptoms. Broadband summary group data provided for internalizing, externalizing, and total with scores of 64+ indicating clinically significant and scores within 60-63 indicating borderline. In Part A, boxplots reflect median and quartile ranges for each group with individual scores represented by the small shapes. The mean and standard deviation scores are represented above the box plots. In Part B: The R and p values represent Spearman correlations between the mean T-score and the individual's age. The bold lines represent the trend for results on the CBCL/1.5-5 and the dotted lines represent the trend for results on the CBCL/6-18.

CBCL/6-18

For SETBP1-HD, the only clinically significant narrowband scale was attention problems (range = 51-88). Borderline narrowband scales included social problems (range = 58–75), thought problems (range = 59-83) and DSM-oriented scales included DSM ADHD (range = 60-70) ([Figure 3](#)).

At the SETBP1-HD individual level, the most common issues reported by 92-100% were easily distracted, speech problems, obsessions, acts young, impulsiveness, clumsy, demands attention, concentration issues, prefers younger kids, picks skin and is too dependent.

For SETBP1-RD results were limited by a small number ($n = 3$). The only clinically significant narrowband scale included thought problems (range = 58-84). Borderline narrowband scales included somatic problems (range = 53-74) and attention problems (range = 64-7) and DSM-oriented scales included DSM somatic problems (range = 50-80).

At the SETBP1-RD individual level, issues reported by 100% of the sample included speech problems, repeats certain acts over and over, acts young, clumsy, concentration issues, bowel movement outside toilet, restless, constipated, and trouble sleeping ([Supplementary Table 4](#)).

Main group effects were not observed at the narrowband scale level, $p > .11$. Group and age interactions were observed for aggressive problems, $F(1, 11) = 5.56$, $p = .038$, such that problems increased for SETBP1-RD but not SETBP1-HD participants with age. Similar trends were observed for conduct, rule-breaking, and thought subdomains, $p < .079$.




Figure 3: Cross-sectional effects for narrowband and DSM-oriented scales on Child Behavior Checklist 6-18. The higher the value, the more severe the symptoms. Summary group data provided for narrowband and DSM-oriented scales with scores of 70+ indicating clinically significant and scores within 65-69 indicating borderline. Boxplots reflect median and quartile ranges for each group with individual scores represented by the small shapes. The mean and standard deviation scores are represented above the box plots.

CBCL/1 ½-5

For SETBP1-HD, the only elevated narrowband scale on the CBCL/1 ½-5 was attention problems (range = 50-80) ([Supplementary Table 5](#)). Elevated scores were notable at the individual level including speech problems by 100% and clumsy and gets into everything by 88%.

For the SETBP1-RD cohort, attention problems, withdrawn, and DSM ADHD were all noted at the borderline level for group mean T-scores and with 67% elevated individual scores. With CBCL/1 ½-5 data provided for only 3 individuals with SETBP1-RD, large standard deviations played a significant impact for mean T-scores at the cohort level. At the individual level, speech problems, quickly shifts between activities, acts too young, and resistance to toilet training were indicated by 100%.

Scores were noted as higher for SETBP1-HD relative to SETBP1-RD for DSM anxiety disorders, $F(1, 7) = 6.79$, $p = .035$, and anxiety and depression, $F(1, 7) = 7.46$, $p = .029$.

Interactions between age and SETBP1 group were noted for DSM ADHD, $F(1, 7) = 8.08$, $p = .025$, such that scores decrease more for older SETBP-RD children relative to SETBP1-HD children.

SRS-2

Caregivers completed the SRS-2 survey at multiple time points for 5 of the 9 SETBP1-HD participants (18 total surveys completed) and for 2 of the 4 SETBP1-RD participants (10 total surveys completed). For SETBP1-HD participants with SRS-2 data 8 of the 9 were male with an age range of 4.3-14.6 years. The cohort showed moderate elevations for the restrictive and repetitive behaviors (RRB, T M = 72.6), social awareness (SA, T M = 69.4), social cognition (SCog, T M = 72.1), social communication (SCom, T M = 68.5), social communication and interaction (SCI, T M = 68.3) and total (T M = 69.9) ([Figure 4A](#)). At an individual level, mild to severe social difficulties were identified at 88.9% for RRB, SC, and SCog, at 77.8% for SA, SCI and total, and at a low 33.3% for social motivation.

For SETBP1-RD participants with SRS-2 data 3 of the 4 were female with an age range of 5.5-16 years. The cohort reflected scores in the moderate range for the subdomains RRB (T M = 69.1), social awareness (T M = 70.1), social communication (T M = 73.4), social cognition (T M = 69.6), and total SRS-2 (T M = 70.7), and a mild elevation for social motivation (T M = 62.9). Total scores for SRS-2 ([Figure 4B](#)) for both SETBP1-HD and SETBP1-RD cohorts were elevated and reflected the overall social deficits observed in symptoms related to ASD.

To compute group differences over time, multilevel linear mixed models with restricted maximum likelihood included a random intercept to account for multiple reports. Longitudinal analysis revealed significant within and between-subject variability for both cohorts. RRB is the only subdomain with a notable increase overtime for the SETBP1-RD cohort (Levene's test: $p = .04$). No effects varied by sex. SETBP1-HD and SETBP1-RD cohort differences were marginal for social motivation with scores lower for the SETBP1-HD cohort than the SETBP1-RD cohort: $F(1, 24) = 5.046$, $p = .0342$.




Figure 4: Cross-sectional and longitudinal effects on SRS-2. Part A reflects mean T-scores for all Social Responsiveness Scale, Revised (SRS-2) surveys for all subdomains for SETBP1-HD and SETBP1-RD cohorts, respectively. The mean t-scores are stated above the reported standard deviations in parentheses. Scores below the line at 60 fell into the normal range, while scores between the 60 mark and the dotted line at 66 were categorized into mild-moderate range, scores between the dotted line at 66 and the bold line at 75 were categorized into the moderate range and scores above the bold line were categorized into the severe range. Part B plotted all T-scores for each participant representing a mixed cross-sectional/longitudinal graph and connected the scores at each given time point for each participant who completed the SRS-2 at more than one time point to reflect observations over time within SETBP1-HD and SETBP1-RD cohorts, respectively, as shown in above and below charts. The R and p values represented Spearman correlations between the mean T-score and the individual's age. Note the marginal effect for social communication interaction (SCI) and social motivation for the SETBP1-HD cohort.

SCQ

SCQ data were available for 12 SETBP1-HD participants (10 male, age range = 4.8-14.3 years). Based on the responses, 4 were considered nonverbal. Only 1 of the 12 individuals scored above the cutoff for likely ASD ≥ 15 .²¹ This individual has an ASD diagnosis; however, the 2 other individuals with an ASD diagnosis who also completed this survey did not score above the threshold. Lower cutoffs have been suggested in literature for differentiating ASD including a cutoff of ≥ 10 or 11.^{30,31,32} Six individuals (50%) scored 11 or higher including one

individual considered nonverbal, although 1 individual with an ASD diagnosis was still not captured with this cutoff.

SCQ data were available for 3 SETBP1-RD participants (2 female, age range = 5.5-16 years). Based on the responses, all were considered non-verbal. Two of the 3 individuals scored above the cutoff ≥ 15 . One of the individuals with a score above the cutoff had an official ASD diagnosis. All 3 individuals scored above the ≥ 11 cutoff.

CSHQ

CSHQ data were available for 14 SETBP1-HD participants (11 male, age range = 2.2-14.3 years). With a total sleep disturbance cut-off score of 41, 9 individuals (64.2%) met the criteria to be evaluated for a potential sleep disorder. Additionally, 3 subscales had scores more than 1 standard deviation above the control mean utilized by the original author: night wakings (4.7), parasomnias (10.5), and daytime sleepiness (12.8) ([Supplementary Table 6](#)).²²

CSHQ data were available for 3 SETBP1-RD participants (all female, age range = 5-10.7 years). With a total sleep disturbance cut-off score of 41, 2 individuals (66.6%) met the criteria to be evaluated for a potential sleep disorder. Additionally, 2 subscales were out of range by more than 2 standard deviations above the control mean utilized by the original author; sleep duration (6.6) and night wakings (5.3) and the bedtime resistance (9.3) subscale was out of range by more than 1 standard deviation above the control mean ([Supplementary Table 6](#)).

Medications

During the MHI, medication data on 18 SETBP1-HD participants revealed 61.1% using stimulants and non-stimulants (e.g., methylphenidate, guanfacine) for ADHD symptoms. Gastrointestinal medications were reported by 44%, melatonin for sleep by 16.7%, behavior medications by 16.7%, anti-anxiety meds by 11.1%, and seizure-related meds by 5.6%. Fish oil, excluding multivitamins, was the most common vitamin supplement at 22.2%, with 75% reporting improvement.

Current medication data was collected for 4 SETBP1-RD participants, with 50% reported taking a stimulant or non-stimulant. Seizure-related medication was reported at 50%; however, only 1 individual reported taking them for seizures. Gastrointestinal medications were reported by 75% and 50% reported taking medications for sleep. Fish oil, excluding multivitamins, was the most common vitamin supplement at 50%, with 100% reporting improvement.

DISCUSSION

Within this paper, we presented the first published findings comparing the neurodevelopmental profiles for individuals with SETBP1-HD and SETBP1-RD. We documented genetic data for 28 individuals with SETBP1-HD and clinical and neurobehavioral details for 22 (12 unpublished).

Additionally, we provided genetic data for 6 individuals with SETBP1-RD and clinical and neurobehavioral details for 5, all previously unpublished cases.

We identified consistent characterization with the SETBP1-HD cohort and previous findings including IDD/DD, speech and language impairment, hypotonia, attention issues, gastrointestinal issues, vision issues, sleep issues, and autistic traits.^{1,4,7,14} These characteristics were also observed in the SETBP1-RD cohort. Notably, both cohorts exhibited a new clinical observation - high pain tolerance. The SETBP1-RD cohort showed clinical comorbidity risks for heart and orthopedic issues, as well as difficulty in bowel control and higher risks for somatic issues compared with the SETBP1-HD cohort. Social motivation emerged as a notable strength for both groups, while repetitive and obsessive behaviors surfaced as a shared challenge. The SETBP1-HD cohort demonstrated relative strength in interpersonal relationships with weaknesses in communication, motor skills, and functioning safely and independently within the community per the VABS-3.

Our findings indicate 100% of SETBP1-HD and SETBP1-RD participants \geq 1 year of age reported delayed first words (>12 months) and phrase speech (>24 months).²⁵ Communication was reported as the greatest deficit domain on the VABS-3 for the SETBP1-HD cohort, which aligns with a previous study's findings, and speech problems were indicated as an area of strong weakness on the CBCLs for both cohorts.⁴ The same study mentioned childhood apraxia of speech (CAS) as the most commonly identified speech diagnosis for children with SETBP1-HD at 80% and that the use of language as reported by phonological errors was additionally impacted. Various publications report that individuals with speech and language difficulties are more likely to have difficulty later in other areas, including attention, socialization, reading, and writing.^{33,34,35} According to ASHA, signs of speech and language delays can be identified as early as birth-3 months.³⁶ Early detection of language and speech delays and initiation of speech therapy for individuals report positive outcomes in communication and other areas of development for individuals with language delays, ID and/or ASD.^{37,38,39,40}

ID/DD were noted for 95% of the individuals with SETBP1-HD and 100% with SETBP1-RD. As a diagnosis of ID now considers adaptive functioning, we also looked at the overall adaptive functioning score on the VABS-3 and noted that all individuals within this study fell in the borderline-mild range.

Despite only 21%-25% reporting an ASD diagnosis for the SETBP1-HD and SETBP1-RD cohorts, the scores for the standardized measures reflect a higher percentage that may warrant further evaluation for an ASD diagnosis and exhibited autistic behaviors, 56% with SETBP1-HD and 100% with SETBP1-RD. Along these same lines, obsessions were noted in all individuals with SETBP1-HD who completed the CBCL/6-18 and repeats certain acts over and over were noted in all individuals with SETBP1-RD who completed the CBCL/6-18. Another predominant characteristic observed was ADHD/attention problems. In the SETBP1-HD cohort, 100% were identified with attention problems (easily distracted, impulsive, and/or concentration issues) on the CBCL/6-18, and 65% reported an ADHD diagnosis and/or were taking medication for associated symptoms. Additionally, 61.1% over the age of 4 reported using stimulants or non-

stimulants including methylphenidate and guanfacine. In the SETBP1-RD cohort, 100% were identified with attention problems on the CBCL/6-18, and 50% reported an ADHD diagnosis and/or were taking medication for associated symptoms.

Sleep issues were reported for 47% with SETBP1-HD and 100% with SETBP1-RD. Clinically meaningful differences in sleep disturbances were noted for 64% of individuals with SETBP1-HD in the CSHQ survey and for 2 individuals (67%) with SETBP1-RD. The use of melatonin was reported in both cohorts to aid in sleep problems.

Gastrointestinal issues affected 57% (diarrhea, constipation, and GERD) with SETBP1-HD and 75% (constipation most prevalent) with SETBP1-RD. The elevated Somatic Complaints and DSM Somatic Problems on the CBCL/6-18 for the SETBP1-RD cohort were due to constipation, aches/pains, nausea, stomachaches, and occasional vomiting reported in 67% of individuals. The SETBP1-RD cohort's struggle with bowel control as noted in the clinical characteristics and the CBCL/6-18 measure could be linked to the high reports of constipation.

Additional studies are needed to explore how the characteristics of individuals with SETBP1-HD and SETBP1-RD change with age. Additionally, there is a need for studies that specifically isolate and examine the unique neurobehavioral and intelligence differences within each cohort. Although facial differences have been identified for individuals with SETBP1 neurodevelopmental disorders, this data is not captured in Searchlight to include for further phenotyping.⁷ Including the individuals reported in this paper, the number of unique individuals with SETBP1-HD reported in publications increases to 76 ([Supplementary Table 7](#)). Presenting the characteristic and phenotype cross-sectional data in this publication for individuals with SETBP1-HD and SETBP1-RD, although limited by a small sample size, is an important step forward for medical management, accurate diagnosis, and clinical trial readiness.

Data Availability

Approved researchers can obtain the Simons Searchlight population dataset described in this study (<https://www.sfari.org/resource/simons-searchlight/>) by applying at <https://base.sfari.org>.

Sources

1. Filges I, Shimojima K, Okamoto N, et al. Reduced expression by SETBP1 haploinsufficiency causes developmental and expressive language delay indicating a phenotype distinct from Schinzel-Giedion syndrome. *J Med Genet.* 2011;48(2):117-122. doi:10.1136/jmg.2010.084582
2. Cardo LF, de la Fuente DC, Li M. Impaired neurogenesis and neural progenitor fate choice in a human stem cell model of SETBP1 disorder. *Mol Autism.* 2023;14(1):8. Published 2023 Feb 20. doi:10.1186/s13229-023-00540-x

3. Piazza R, Magistroni V, Redaelli S, et al. SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. *Nat Commun.* 2018;9(1):2192. Published 2018 Jun 6. doi:10.1038/s41467-018-04462-8
4. Morgan A, Braden R, Wong MMK, et al. Speech and language deficits are central to SETBP1 haploinsufficiency disorder. *Eur J Hum Genet.* 2021;29(8):1216-1225. doi:10.1038/s41431-021-00894-x
5. Schinzel A, Giedion A. A syndrome of severe midface retraction, multiple skull anomalies, clubfeet, and cardiac and renal malformations in sibs. *Am J Med Genet.* 1978;1(4):361-375. doi:10.1002/ajmg.1320010402
6. Acuna-Hidalgo R, Deriziotis P, Steehouwer M, et al. Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies. *PLoS Genet.* 2017;13(3):e1006683. Published 2017 Mar 27. doi:10.1371/journal.pgen.1006683
7. Jansen NA, Braden RO, Srivastava S, et al. Clinical delineation of SETBP1 haploinsufficiency disorder. *Eur J Hum Genet.* 2021;29(8):1198-1205. doi:10.1038/s41431-021-00888-9
8. Hoischen A, van Bon BW, Gilissen C, et al. De novo mutations of SETBP1 cause Schinzel-Giedion syndrome. *Nat Genet.* 2010;42(6):483-485. doi:10.1038/ng.581
9. Lehman AM, McFadden D, Pugash D, Sangha K, Gibson WT, Patel MS. Schinzel-Giedion syndrome: report of splenopancreatic fusion and proposed diagnostic criteria. *Am J Med Genet A.* 2008;146A(10):1299-1306. doi:10.1002/ajmg.a.32277 - change to 7
10. Leonardi E, Bettella E, Pelizza MF, et al. Identification of SETBP1 Mutations by Gene Panel Sequencing in Individuals With Intellectual Disability or With "Developmental and Epileptic Encephalopathy". *Front Neurol.* 2020;11:593446. Published 2020 Dec 16. doi:10.3389/fneur.2020.593446
11. Wong MM, Kampen RA, Braden RO, et al. SETBP1 variants outside the degron disrupt DNA-binding and transcription independent of protein abundance to cause a heterogeneous neurodevelopmental disorder. *medRxiv.* Preprint posted online 2022. doi:10.1101/2022.03.04.22271462
12. Morgan A, Srivastava S, Duis J, et al. SETBP1 Haploinsufficiency Disorder. 2021 Nov 18. In: Adam MP, Mirzaa GM, Pagon RA, et al, editors. *GeneReviews®* [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK575336/>
13. Antonyan L, Ernst C. Putative Roles of SETBP1 Dosage on the SET Oncogene to Affect Brain Development. *Front Neurosci.* 2022;16:813430. Published 2022 May 24. doi:10.3389/fnins.2022.813430
14. Coe BP, Witherspoon K, Rosenfeld JA, et al. Refining analyses of copy number variation identifies specific genes associated with developmental delay. *Nat Genet.* 2014;46(10):1063-1071. doi:10.1038/ng.3092

15. Riggs NR, Rigles B, Schworer E, et al. Community-based participatory approaches to neurogenetic syndrome research. *Int Rev Res Dev Disa*. 2020;58:157-186. doi:10.1016/bs.irrdd.2020.07.007
16. Sparrow SS, Cicchetti DV, Saulnier CA. *Vineland Adaptive Behavior Scales*. 3rd ed. San Antonio, TX, Pearson; 2016
17. Achenbach TM, Rescorla LA. *Manual for the ASEBA preschool forms & profiles: an integrated system of multi-informant assessment*. ASEBA; 2000.
18. Achenbach TM. *Manual for ASEBA school-age forms & profiles*. University of Vermont, Research Center for Children, Youth & Families. 2001.
19. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 5th ed. Washington D.C.; 2013.
20. Constantino JH, Gruber CP. *Social responsiveness scale-second edition (SRS-2)*. Torrance, CA: Western Psychological Services; 2012
21. Rutter M, Bailey A, Lord C. *The social communication questionnaire*. Los Angeles, CA: Western Psychological Services; 2003
22. Owens JA, Spirito A, McGuinn M. The Children's Sleep Habits Questionnaire (CSHQ): psychometric properties of a survey instrument for school-aged children. *Sleep*. 2000;23(8):1043-1051.
23. Ingram DG, Raje N, Arganbright JM. Sleep profiles in children with 22q deletion syndrome: a study of 100 consecutive children seen in a multidisciplinary clinic. *J Clin Sleep Med*. 2023;19(1):27-34. doi:10.5664/jcsm.10238
24. Freeman PJ, Hart RK, Gretton LJ, Brookes AJ, Dalglish R. VariantValidator: Accurate validation, mapping and formatting of sequence variation descriptions. *Human Mutation*. 2018;39:61-68. <https://doi.org/10.1002/humu.23348>.
25. CDC Centers for Disease Control and Prevention. Learn the Signs. Act Early. Accessed 23 October 2023. <https://www.cdc.gov/ncbddd/actearly/>.
26. Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents [published correction appears in *Pediatrics*. 2020 Mar;145(3):]. *Pediatrics*. 2019;144(4):e20192528. doi:10.1542/peds.2019-2528
27. Hyman SL, Levy SE, Myers SM. Council on Children with Disabilities, Section on Developmental and Behavioral Pediatrics. Identification, Evaluation, and Management of Children With Autism Spectrum Disorder. *Pediatrics*. 2020;145(1):e20193447. doi:10.1542/peds.2019-3447
28. Mazefsky CA, Anderson R, Conner CM, Minshew N. Child Behavior Checklist Scores for School-Aged Children with Autism: Preliminary Evidence of Patterns Suggesting the Need for Referral. *J Psychopathol Behav Assess*. 2011;33(1):31-37. doi:10.1007/s10862-010-9198-1

29. Onis, M. WHO Motor development study: Windows of achievement for six gross motor development milestones. *Acta Paediatric Supplement*; 2006;450:86–95.
30. Schwenck C, Freitag CM. Differentiation between attention-deficit/hyperactivity disorder and autism spectrum disorder by the social communication questionnaire. *Atten Defic Hyperact Disord*. 2014;6(3):221-229. doi:10.1007/s12402-014-0147-9
31. Corsello C, Hus V, Pickles A, et al. Between a ROC and a hard place: decision making and making decisions about using the SCQ. *Journal of child psychology and psychiatry*. 2007;48(9):932-940. doi:10.1111/j.1469-7610.2007.01762.x
32. Guttentag S, Bishop S, Doggett R, et al. The utility of parent-report screening tools in differentiating autism versus attention-deficit/hyperactivity disorder in school-age children. *Autism*. 2022;26(2):473-487. doi:10.1177/13623613211030071
33. Snowling MJ, Bishop DV, Stothard SE, Chipchase B, Kaplan C. Psychosocial outcomes at 15 years of children with a preschool history of speech-language impairment. *J Child Psychol Psychiatry*. 2006;47(8):759-765. doi:10.1111/j.1469-7610.2006.01631.x
34. Bishop DV, Clarkson B. Written language as a window into residual language deficits: a study of children with persistent and residual speech and language impairments. *Cortex*. 2003;39(2):215-237. doi:10.1016/s0010-9452(08)70106-0
35. McLaughlin MR. Speech and language delay in children. *Am Fam Physician*. 2011;83(10):1183-1188
36. American Speech-Language- Hearing Association. Early Identification of Speech, Language, and Hearing Disorders. Accessed 23 October 2023. <https://www.asha.org/public/early-identification-of-speech-language-and-hearing-disorders/>
37. Vermeij BAM, Wiefferink CH, Knoors H, Scholte RHJ. Effects in language development of young children with language delay during early intervention. *J Commun Disord*. 2023;103:106326. doi:10.1016/j.jcomdis.2023.106326
38. Marrus N, Hall L. Intellectual Disability and Language Disorder. *Child Adolesc Psychiatr Clin N Am*. 2017;26(3):539-554. doi:10.1016/j.chc.2017.03.001
39. Osman HA, Haridi M, Gonzalez NA, et al. A Systematic Review of the Efficacy of Early Initiation of Speech Therapy and Its Positive Impact on Autism Spectrum Disorder. *Cureus*. 2023;15(3):e35930. Published 2023 Mar 9. doi:10.7759/cureus.35930
40. Jullien S. Screening for language and speech delay in children under five years. *BMC Pediatr*. 2021;21(Suppl 1):362. Published 2021 Sep 8. doi:10.1186/s12887-021-02817-7